The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.
 
Matthew H. Taylor
Honoraria - Bayer; Bristol Myers Squibb Foundation; Eisai; Merck; Pfizer; Regeneron
Consulting or Advisory Role - ArQule; Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Merck
Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Loxo/Bayer (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
 
Rom S. Leidner
No Relationships to Disclose
 
Richard Bryan Bell
No Relationships to Disclose
 
Bernard Fox
No Relationships to Disclose
 
Hong Xiao
No Relationships to Disclose
 
Marcus Couey
No Relationships to Disclose
 
Andrew Baker
No Relationships to Disclose
 
George Morris
No Relationships to Disclose
 
Lessli Rushforth
No Relationships to Disclose